Get started
GILEAD SCIENCESGILEAD SCIENCESGILEAD SCIENCES

GILEAD SCIENCES

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

GIS chart


Full chart

Key facts today

Gilead Sciences, Inc. saw a 22.1% rise in market value after the FDA fast-tracked Livdelzi and approved Trodelvy for HR-/HER2- breast cancer in Japan.
Analyze the impactAnalyze the impact

GIS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪104.91 B‬ CHF
Dividend yield (indicated)
3.19%
Price to earnings Ratio (TTM)
1,022.426
Basic EPS (TTM)
0.085 CHF
Net income (FY)
‪4.77 B‬ CHF
Revenue (FY)
‪22.78 B‬ CHF
Shares float
‪1.24 B‬
Beta (1Y)
0.33

Employees


Employees (FY)
‪18 K‬
Change (1Y)
‪+1 K‬ +5.88%
Revenue / Employee (1Y)
‪1.50 M‬ CHF
Net income / Employee (1Y)
‪314.67 K‬ CHF

About Gilead Sciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Daniel P. O'Day
Website
gilead.com
Headquarters
Foster City
Founded
1987
FIGI
BBG006TLQ7X8
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

GIS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

GIS highest yielding bonds


GISE
GILEAD SCIENCES 2046
Yield to maturity
5.33%
Maturity date
Mar 1, 2046
GILD4104362
Gilead Sciences, Inc. 4.8% 01-APR-2044
Yield to maturity
5.33%
Maturity date
Apr 1, 2044
GILD5648609
Gilead Sciences, Inc. 5.55% 15-OCT-2053
Yield to maturity
5.32%
Maturity date
Oct 15, 2053
GILD.GO
Gilead Sciences, Inc. 5.65% 01-DEC-2041
Yield to maturity
5.32%
Maturity date
Dec 1, 2041
GILD4184058
Gilead Sciences, Inc. 4.5% 01-FEB-2045
Yield to maturity
5.31%
Maturity date
Feb 1, 2045
US375558BK8
GILEAD SCIENCES 16/47
Yield to maturity
5.28%
Maturity date
Mar 1, 2047
US375558BS1
GILEAD SCIEN 20/40
Yield to maturity
5.11%
Maturity date
Oct 1, 2040
GISG
GILEAD SCIENCES 16/36
Yield to maturity
5.07%
Maturity date
Sep 1, 2036
GISF
GILEAD SCIENCES 2035
Yield to maturity
5.01%
Maturity date
Sep 1, 2035
GILD5050849
Gilead Sciences, Inc. 2.8% 01-OCT-2050
Yield to maturity
4.98%
Maturity date
Oct 1, 2050
GILD5648658
Gilead Sciences, Inc. 5.25% 15-OCT-2033
Yield to maturity
4.90%
Maturity date
Oct 15, 2033

Explore more bonds 

Sparks


Curated watchlists where GIS is featured.

See all sparks 

Frequently Asked Questions


The current price of GIS is 84.244 CHF — it has increased by 12.55% in the past 24 hours. Watch GILEAD SCIENCES stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange GILEAD SCIENCES stocks are traded under the ticker GIS.
GIS stock has risen by 12.55% compared to the previous week, the month change is a 19.58% rise, over the last year GILEAD SCIENCES has showed a 20.34% increase.
We've gathered analysts' opinions on GILEAD SCIENCES future price: according to them, GIS price has a max estimate of 107.33 CHF and a min estimate of 60.21 CHF. Watch GIS chart and read a more detailed GILEAD SCIENCES stock forecast: see what analysts think of GILEAD SCIENCES and suggest that you do with its stocks.
GIS reached its all-time high on Dec 1, 2022 with the price of 82.529 CHF, and its all-time low was 54.936 CHF and was reached on Mar 28, 2022. View more price dynamics on GIS chart.
See other stocks reaching their highest and lowest prices.
GIS stock is 11.50% volatile and has beta coefficient of 0.33. Track GILEAD SCIENCES stock price on the chart and check out the list of the most volatile stocks — is GILEAD SCIENCES there?
Today GILEAD SCIENCES has the market capitalization of ‪104.91 B‬, it has decreased by −0.54% over the last week.
Yes, you can track GILEAD SCIENCES financials in yearly and quarterly reports right on TradingView.
GILEAD SCIENCES is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
GIS earnings for the last quarter are 1.71 CHF per share, whereas the estimation was 1.30 CHF resulting in a 32.02% surprise. The estimated earnings for the next quarter are 1.52 CHF per share. See more details about GILEAD SCIENCES earnings.
GILEAD SCIENCES revenue for the last quarter amounts to ‪6.39 B‬ CHF, despite the estimated figure of ‪5.95 B‬ CHF. In the next quarter, revenue is expected to reach ‪6.24 B‬ CHF.
GIS net income for the last quarter is ‪1.06 B‬ CHF, while the quarter before that showed ‪1.45 B‬ CHF of net income which accounts for −26.82% change. Track more GILEAD SCIENCES financial stats to get the full picture.
Yes, GIS dividends are paid quarterly. The last dividend per share was 0.65 CHF. As of today, Dividend Yield (TTM)% is 3.17%. Tracking GILEAD SCIENCES dividends might help you take more informed decisions.
GILEAD SCIENCES dividend yield was 3.70% in 2023, and payout ratio reached 66.62%. The year before the numbers were 3.40% and 80.25% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 9, 2024, the company has ‪18.00 K‬ employees. See our rating of the largest employees — is GILEAD SCIENCES on this list?
Like other stocks, GIS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GILEAD SCIENCES stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GILEAD SCIENCES technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GILEAD SCIENCES stock shows the strong buy signal. See more of GILEAD SCIENCES technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.